RetinalGenix Technologies (RTGN) Notes Payables (2022 - 2026)
RetinalGenix Technologies (RTGN) reported Notes Payables of $49000.0 for Q1 2026, little changed sequentially from $49000.0 in Q4 2025.
RetinalGenix Technologies (RTGN) Notes Payables (2022 - 2026) Analysis & Trends
RetinalGenix Technologies (RTGN) has 4 years of Notes Payables data on file, last reported at $49000.0 in Q1 2026.
- For the quarter ending Q1 2026, Notes Payables changed N/A year-over-year to $49000.0; the trailing twelve-month figure through Mar 2026 stood at $49000.0 (changed N/A YoY), and the FY2025 full-year result was $49000.0, changed N/A from the prior year.
- Notes Payables steadied at $49000.0 in Q1 2026, from $49000.0 in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $49000.0 in Q4 2022 to a low of $49000.0 in Q4 2022.
- A 4-year average of $49000.0 and a median of $49000.0 in 2022 frame the typical range for Notes Payables.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49,000.00 |
| Dec 31, 2025 | 49,000.00 |
| Sep 30, 2023 | 49,000.00 |
| Dec 31, 2022 | 49,000.00 |